$2.68▴ 1.52%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
AC Immune SA's earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days5 articles
3 bullish2 neutral0 bearish
Vertex Posts Positive Phase II Data on Kidney Disease Drug
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce- XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Definium Reports Second Phase III Success in Anxiety Disorder Program- GSK Presents Jideytro Data for Potential Use in First-Line NSCLC